GB 3
Alternative Names: GB-3Latest Information Update: 28 Feb 2025
At a glance
- Originator Geneva Biotech
- Class Antifibrotics; Antihyperlipidaemics
- Mechanism of Action Lipid metabolism modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Dyslipidaemias; Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Dyslipidaemias in Switzerland
- 28 Feb 2025 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in Switzerland
- 04 Jan 2021 GB 3 is available for licensing as of 04 Jan 2021. https://geneva-biotech.com/